ZL-6201 / ZAI Lab - LARVOL DELTA

ZL-6201, a novel LRRC15-targeting antibody drug conjugate, modifies tumor microenvironment in epithelia solid tumor models (SITC 2026) - No abstract available

ADC • Preclinical • Tumor microenvironment • Oncology • Solid Tumor • LRRC1

Anticipated Major Milestones:…ZL-6201 (LRRC15 ADC) (Businesswire) - "Provide topline results from the dose-escalation portion of the global Phase 1a/b study evaluating ZL-6201 in patients with sarcoma and selected tumors in the first half of 2027."

P1 data • Sarcoma

Discovery of ZL-6201, a novel LRRC15-targeting antibody drug conjugate (ADC) for the treatment of sarcomas and epithelial solid tumors (AACR 2026) - "Both ZL-6201 and the surrogate were well tolerated and demonstrated dose-dependent anti-tumor activity. Finally, ZL-6201 showed acceptable toxicokinetic and safety profiles in non-human primates (NHP).Collectively, these data support advancing ZL-6201 into clinical development as a therapeutic candidate for sarcomas and epithelial solid tumors characterized by LRRC15 expression within the tumor microenvironment."

ADC • Brain Cancer • Glioblastoma • Melanoma • Oncology • Sarcoma • Solid Tumor • CAFs • LRRC1

Data from two additional Zai Lab internally developed investigational oncology therapies will also be presented at AACR (Businesswire) - "Researchers will share promising findings from preclinical studies of ZL-6201, a leucine-rich repeat-containing protein 15 (LRRC15) targeting ADC for the treatment of sarcoma and epithelial tumors with LRRC15 expressing cancer-associated fibroblasts; and, ZL-1222, a potential next generation anti-PD-1 and interleukin-12 (IL-12) signaling attenuated mutein agonist immunocytokine for cancer immunotherapy."

Preclinical • Sarcoma

Discovery and characterization of a novel LRRC15-targeting antibody drug conjugate (ADC) for the treatment of solid tumors (AACR 2025) - "In a human chondrosarcoma SA4109 PDX model, a significantly higher concentration of payload and ADC were detected in the tumors compared to mouse serum, indicating targeted delivery of the ADC. Collectively, these findings support advancing ZL-6201 into IND-enabling studies as a potential treatment for patients with sarcoma and other LRRC15-positive solid tumors."

ADC • Brain Cancer • CNS Tumor • Glioblastoma • Melanoma • Oncology • Sarcoma • Solid Tumor • CAFs • LRRC1

Zai Lab to Present New Data on Three Internally Developed Oncology Candidates at AACR 2026, Including Zocilurtatug Pelitecan, a DLL3-Targeting Antibody-Drug Conjugate (ADC) (Businesswire) - "Zoci data show intracranial response in small-cell lung cancer (SCLC) with brain metastases, as well as activity in other neuroendocrine carcinomas. ZL-6201 will be highlighted in a poster presentation showcasing its potential as an innovative ADC for the treatment of sarcoma and other LRRC15-positive solid tumors. ZL-1222, a PD-1/IL-12, will also be featured in a poster presentation highlighting its potential as a next-generation immunocytokine therapy for the treatment of solid tumors....Zoci is on track to become Zai Lab’s first global oncology launch, with plans for three registration-enabling studies across 2L+ SCLC, 1L SCLC, and extrapulmonary NECs by the end of 2026."

Clinical data • New trial • Neuroendocrine Carcinoma • Sarcoma • Small Cell Lung Cancer

Phase 1a/b Study of ZL-6201 Safety, PK, and Preliminary Efficacy in Sarcoma and Selected Tumors (clinicaltrials.gov) - P1 | N=180 | Recruiting | Sponsor: Zai Lab (Shanghai) Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Oncology • Sarcoma • Solid Tumor

Phase 1a/b Study of ZL-6201 Safety, PK, and Preliminary Efficacy in Sarcoma and Selected Tumors (clinicaltrials.gov) - P1 | N=180 | Not yet recruiting | Sponsor: Zai Lab (Shanghai) Co., Ltd.

New P1 trial • Oncology • Sarcoma • Solid Tumor

Expected Clinical Developments and Data Readouts:…ZL-6201 (LRRC15 ADC) (Businesswire) - "Zai Lab to submit an Investigational New Drug application to the FDA for a global Phase 1 study for patients with sarcoma and potentially other LRRC15-positive solid tumors in the fourth quarter of 2025."

IND • Sarcoma

Zai Lab Presents Data Highlighting Potential of Internally Developed, Next-Generation Oncology Therapies at AACR 2025 (Businesswire) - "Findings to be presented at AACR 2025 on Tuesday, April 29, demonstrate that ZL-6201 efficiently internalizes within and kills tumor cells, while also exhibiting a strong bystander killing effect in the tumor microenvironment where the target is often expressed. In multiple in vitro and in vivo pre-clinical studies, treatment with ZL-6201 effectively suppressed the growth of established tumors. Based on these findings, Zai Lab plans to initiate Investigational New Drug (IND)-enabling studies of ZL-6201 as a potential treatment for patients with sarcoma and other LRRC15-positive solid tumors, such as breast cancer and other malignancies, in 2025....Findings from preclinical studies to be presented Monday, April 28, at AACR 2025 suggest that ZL-1222, through precisely tailored IL-12 activity and PD-1 targeting, demonstrate potent anti-tumor activity in both anti-PD-1 sensitive and resistant tumor models, with improved systemic safety."

Preclinical • Breast Cancer • Hematological Malignancies • Sarcoma • Solid Tumor

Zai Lab to Present New Data from Internally Developed, Next-Generation Oncology Candidates at AACR 2025 Annual Meeting (Businesswire) - "Poster presentation will highlight the potential of ZL-6201 as an innovative antibody-drug conjugate (ADC) for the treatment of sarcoma and other leucine-rich repeat-containing protein 15 (LRRC15)-positive solid tumors. Late-breaking poster presentation will summarize data from preclinical evaluation of ZL-1222, a promising next-generation interleukin-12 (IL-12) immunocytokine therapy for the treatment of various cancers."

Late-breaking abstract • Preclinical • Sarcoma • Solid Tumor

Zai Lab Announces Strategic Partnership with MediLink Therapeutics to Develop a Novel LRRC15 Antibody-Drug Conjugate (Businesswire) - "Zai Lab Limited...announced a new strategic collaboration and worldwide license agreement with MediLink Therapeutics...to use MediLink’s TMALIN antibody-drug conjugate (ADC) platform for the development of a novel LRRC15 ADC, ZL-6201, consisting of an antibody discovered by Zai Lab. Through this collaboration, Zai Lab further expands its global oncology pipeline with another potential first-in-class ADC targeting multiple solid tumors and addressing significant unmet medical needs. ZL-6201 has demonstrated encouraging preclinical data with an IND expected to be filed in 2025."

IND • Licensing / partnership • Solid Tumor